Bcl-2/Bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 status - PubMed (original) (raw)

Bcl-2/Bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 status

J F Mirjolet et al. Br J Cancer. 2000 Nov.

Abstract

p53 tumour-suppressor gene is involved in cell growth control, arrest and apoptosis. Nevertheless cell cycle arrest and apoptosis induction can be observed in p53-defective cells after exposure to DNA-damaging agents such as 5-fluorouracil (5-FU) suggesting the importance of alternative pathways via p53-independent mechanisms. In order to establish relationship between p53 status, cell cycle arrest, Bcl-2/Bax regulation and 5-FU sensitivity, we examined p53 mRNA and protein expression and p53 protein functionality in wild-type (wt) and mutant (mt) p53 cell lines. p53 mRNA and p53 protein expression were determined before and after exposure to equitoxic 5-FU concentration in six human carcinoma cell lines differing in p53 status and displaying marked differences in 5-FU sensitivity, with IC(50)values ranging from 0.2-22.6 mM. 5-FU induced a rise in p53 mRNA expression in mt p53 cell lines and in human papilloma virus positive wt p53 cell line, whereas significant decrease in p53 mRNA expression was found in wt p53 cell line. Whatever p53 status, 5-FU altered p53 transcriptional and translational regulation leading to up-regulation of p53 protein. In relation with p53 functionality, but independently of p53 mutational status, after exposure to 5-FU equitoxic concentration, all cell lines were able to arrest in G1. No relationship was evidenced between G1 accumulation ability and 5-FU sensitivity. Moreover, after 5-FU exposure, Bax and Bcl-2 proteins regulation was under p53 protein control and a statistically significant relationship (r = 0.880, P = 0.0097) was observed between Bcl-2/Bax ratio and 5-FU sensitivity. In conclusion, whatever p53 status, Bcl-2 or Bax induction and Bcl-2/Bax protein ratio were correlated to 5-FU sensitivity.

PubMed Disclaimer

Cited by

The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines.
Ma Y, Sender S, Sekora A, Kong W, Bauer P, Ameziane N, Al-Ali R, Krake S, Radefeldt M, Weiss FU, Lerch MM, Parveen A, Zechner D, Junghanss C, Murua Escobar H. Ma Y, et al. Int J Mol Sci. 2022 Apr 13;23(8):4295. doi: 10.3390/ijms23084295. Int J Mol Sci. 2022. PMID: 35457111 Free PMC article.
IFNgamma restores breast cancer sensitivity to fulvestrant by regulating STAT1, IFN regulatory factor 1, NF-kappaB, BCL2 family members, and signaling to caspase-dependent apoptosis.
Ning Y, Riggins RB, Mulla JE, Chung H, Zwart A, Clarke R. Ning Y, et al. Mol Cancer Ther. 2010 May;9(5):1274-85. doi: 10.1158/1535-7163.MCT-09-1169. Mol Cancer Ther. 2010. PMID: 20457620 Free PMC article.
A double-modulation strategy in cancer treatment with a chemotherapeutic agent and siRNA.
Nakamura K, Abu Lila AS, Matsunaga M, Doi Y, Ishida T, Kiwada H. Nakamura K, et al. Mol Ther. 2011 Nov;19(11):2040-7. doi: 10.1038/mt.2011.174. Epub 2011 Aug 30. Mol Ther. 2011. PMID: 21878904 Free PMC article.
The apoptotic effect of D Rhamnose β-hederin, a novel oleanane-type triterpenoid saponin on breast cancer cells.
Cheng L, Xia TS, Wang YF, Zhou W, Liang XQ, Xue JQ, Shi L, Wang Y, Ding Q. Cheng L, et al. PLoS One. 2014 Mar 6;9(6):e90848. doi: 10.1371/journal.pone.0090848. eCollection 2014. PLoS One. 2014. PMID: 24603880 Free PMC article.

References

1. Cancer Res. 1993 Oct 15;53(20):4776-80 - PubMed
1. EMBO J. 1993 Feb;12(2):461-8 - PubMed
1. Cell. 1993 Nov 19;75(4):817-25 - PubMed
1. Cancer Chemother Pharmacol. 1993;33(2):163-70 - PubMed
1. J Cell Biol. 1994 Jan;124(1-2):1-6 - PubMed

Bcl-2/Bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 status - PubMed (original) (raw)